Glioblastoma Clinical Trial
Official title:
Phase I Dose Escalation of Vandetanib (Zactima, ZD6474) in Combination With Etoposide for Malignant Gliomas
Primary Objective: To determine maximum tolerated dose & dose limiting toxicity of
vandetanib when combined with standard dosing of etoposide among patients with recurrent
malignant glioma who are on & not on enzyme-inducing anti-epileptic drugs (EIAEDs) Secondary
Objectives: To assess safety & tolerability of vandetanib + etoposide in this population; To
evaluate pharmacokinetics of vandetanib among malignant glioma patients on & not on EIAEDs
when combined with etoposide.
Exploratory Objective: To evaluate for evidence of anti-tumor activity of study regimen
among recurrent malignant glioma patients including radiographic response rate, 6-month
progression free survival (PFS) rate & median PFS.
This is open-label, single center, 2-cohort phase I dose-escalation study of vandetanib
administered orally on continuous daily dosing schedule + oral etoposide among adult
patients with recurrent or relapsing malignant glioma. Patients will be stratified based on
whether they are receiving EIAEDs & each stratum will independently dose escalate. Dose of
vandetanib will be increased in successive cohorts of patients. Etoposide will be given
daily at a dose of 50mg/day for 21 days followed by 7 days with no etoposide. Cohorts of 3-6
subjects will accrue at each dose level until maximum tolerated dose (MTD) is defined.
Subjects will be adult patients with histologically confirmed malignant glioma who are
presenting at time of recurrence/relapse. Up to 48 subjects will be enrolled.
Sample size will be based on modified, classical "3+3" dose escalation design. Primary
safety & efficacy analysis will be conducted on all subject data at time all subjects who
are still receiving study drug will have completed at least 4 cycles of treatment. Most
common adverse events (AEs) associated with vandetanib are rash, diarrhea, & asymptomatic
QTc prolongation. Protracted oral dosing of etoposide is associated with toxicity that is
mild in most patients & consists mainly of myelosuppression & diarrhea. Less commonly,
protracted etoposide dosing has been associated w more significant hematologic toxicity.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05664243 -
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Recruiting |
NCT05635734 -
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03679754 -
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
|
Phase 1 | |
| Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
| Terminated |
NCT03927222 -
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
|
Phase 2 | |
| Recruiting |
NCT03897491 -
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03587038 -
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT04391062 -
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03661723 -
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT02655601 -
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
|
Phase 2 | |
| Completed |
NCT02206230 -
Trial of Hypofractionated Radiation Therapy for Glioblastoma
|
Phase 2 | |
| Completed |
NCT03493932 -
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
|
Phase 1 | |
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Completed |
NCT03018288 -
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
|
Phase 2 | |
| Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
| Not yet recruiting |
NCT04552977 -
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Terminated |
NCT02905643 -
Discerning Pseudoprogression vs True Tumor Growth in GBMs
|